GLP-1 RA Regulatory Safety Alerts
Active safety communications, boxed warnings, pharmacovigilance signals, and guideline updates from major regulatory authorities. Source-checked 29 June 2026; jurisdiction-specific wording is labelled explicitly.
High-priority safety signals currently active across GLP-1 RA class. All prescribers should be aware of these.
In rodents, liraglutide, semaglutide, dulaglutide, exenatide and other GLP-1 RAs cause dose-dependent and treatment-duration-dependent thyroid C-cell adenomas and carcinomas. It is unknown whether GLP-1 RAs cause thyroid C-cell tumours in humans.
US prescribing information for affected products contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is United States jurisdiction wording and must not be presented as a universal UK/EU class contraindication.
UK distinction: Current UK SmPC contraindications are product-specific; for Wegovy and Mounjaro, section 4.3 lists hypersensitivity. Check the current UK SmPC rather than importing US boxed-warning language into UK prescribing decisions.
GLP-1 RAs and dual GIP/GLP-1 receptor agonists slow gastric emptying and may leave residual gastric contents despite standard pre-procedure fasting. MHRA guidance published 28 January 2025 advises anaesthetists to include GLP-1/GIP-GLP-1 use in the aspiration-risk assessment and to ask specifically because private prescriptions may not appear in the medical record.
Action required: Inform the anaesthetist and procedural team that the patient is using a GLP-1 or dual GIP/GLP-1 medicine. Use individualised risk assessment for symptoms such as nausea, vomiting, abdominal pain, reflux or known gastroparesis. The MHRA advice says patients should take prescribed medicines as usual and should not stop without discussing with their doctor; local anaesthetic guidance should determine procedural management.
Aligned with MHRA DSU January 2025 and the January 2025 Association of Anaesthetists multidisciplinary consensus statement.
MHRA updated product information for all UK-authorised GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists on 29 January 2026 to highlight rare severe acute pancreatitis reports, including necrotising and fatal cases.
Action required: Advise patients to seek urgent medical attention for severe, persistent abdominal pain that may radiate to the back and may be accompanied by nausea and vomiting. Stop treatment immediately if pancreatitis is suspected and do not restart if pancreatitis is confirmed. Use caution in patients with a history of pancreatitis.
FDA Drug Safety Communication dated 13 January 2026 states that FDA’s comprehensive review did not identify an increased risk of suicidal ideation or behaviour with GLP-1 RA medicines and requests removal of this warning language from affected Saxenda, Wegovy and Zepbound labelling.
Clinical framing: This resolves the regulatory signal rather than removing the need for ordinary mental-health assessment. New or worsening depression, suicidal thoughts or unusual mood/behaviour changes still require prompt clinical response.
Gastroparesis added as adverse reaction across GLP-1 RA SmPCs (2024). Screen for symptoms before initiation. Cases reported with both short- and long-acting agents; onset may be insidious.
Action required: Enquire about gastroparesis symptoms at initiation and follow-up. Consider withholding if symptomatic gastroparesis develops. Gastroparesis can persist after drug cessation.
FDA added ileus as an adverse reaction to semaglutide and tirzepatide labelling following pharmacovigilance signal (2024). Cases resolved on drug discontinuation in most reports.
Action required: Hold GLP-1 RA in any patient presenting with features of ileus (absent bowel sounds, distension, vomiting, abdominal pain). Do not re-challenge without specialist review.
FDA’s 2026 communication states that a comprehensive review did not identify an increased risk of suicidal ideation or behaviour with GLP-1 RA medications. FDA requested removal of the warning from affected Saxenda, Wegovy and Zepbound labelling so obesity and diabetes GLP-1 RA labelling communicates the signal consistently.
Evidence reviewed by FDA: placebo-controlled trial meta-analysis, FDA Sentinel claims analysis, post-marketing reports and published observational studies. Continue routine mental-health assessment and refer urgently if suicidal thoughts are disclosed.
FDA warns that unapproved semaglutide and tirzepatide products do not undergo FDA review for safety, effectiveness or quality before marketing. Dosing errors have been reported with compounded injectable semaglutide products, including confusion between milligrams, units and multi-dose vial concentrations.
Clinical action: Verify product source, strength, dose units and patient understanding. Use compounded medicines only where a patient’s medical need cannot be met by an FDA-approved product and report product-quality or dosing problems through FDA MedWatch.
FDA updated prescribing information for all GLP-1 RAs to add warnings about pulmonary aspiration risk, particularly during sedation and general anaesthesia. Delayed gastric emptying — a pharmacological effect of GLP-1 RAs — can result in retained gastric contents even after standard pre-procedural fasting periods.
Prescribing information update: Healthcare providers should inform patients scheduled for procedures requiring anaesthesia or deep sedation. Consider following pre-procedural fasting guidelines and inform the anaesthesia team of patient's GLP-1 RA use.
Following pharmacovigilance analysis, FDA added ileus as a listed adverse reaction in semaglutide and tirzepatide US prescribing information. Mechanism likely relates to GLP-1 RA-mediated reduction in intestinal motility.
Following review of FAERS and EudraVigilance reports, EMA PRAC recommended that alopecia (hair loss) be added to the product information for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Hair loss is typically transient and reversible, and is thought to occur via telogen effluvium — a physiological response to rapid weight loss and caloric restriction rather than a direct drug effect.
Clinical advice: Counsel patients that hair loss, if it occurs, typically resolves within 3–6 months. Ensure adequate nutritional intake. No dose adjustment required. Refer to dermatology if persistent.
Following a systematic review of available data (2023–2024), EMA PRAC concluded that there is no causal relationship between GLP-1 RA use and suicidal ideation or self-harm behaviour. The signal has been closed as "no new safety concern."
This arose from spontaneous reports and social media signals. The PRAC review included pharmacoepidemiological data, non-clinical studies, and clinical trial data. Note: Depression and obesity are independent risk factors for suicidal ideation; confounding is likely in spontaneous reports.
Note: Some EMA product information may still carry a precautionary statement pending final label updates. Check current SmPC for each product.
EMA updated SmPCs to include gastroparesis as an adverse event requiring clinical monitoring. Pharmacovigilance remains ongoing. PRAC recommended healthcare providers screen for symptoms of gastric dysmotility before initiating GLP-1 RA therapy.
MHRA Drug Safety Update (28 January 2025) highlighted the potential risk of pulmonary aspiration in patients taking GLP-1 or dual GIP/GLP-1 receptor agonists who undergo general anaesthesia or deep sedation.
Key recommendations:
- Ask specifically about GLP-1 and dual GIP/GLP-1 medicines, including private prescriptions that may not be in the medical record
- Identify aspiration risk early, especially at pre-assessment clinic
- Consider higher risk with diabetic gastroparesis, obesity, reflux disease, nausea, vomiting or abdominal pain
- Use individualised anaesthetic risk assessment and usual aspiration-risk management
- Advise patients to inform their healthcare team and anaesthetist before procedures
- Report suspected aspiration and surgical complications via Yellow Card
Product information for dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide has been further updated to highlight potential severe acute pancreatitis, including rare necrotising and fatal cases. MHRA reports 1,296 Yellow Card pancreatitis reports associated with GLP-1 or dual GIP/GLP-1 medicines between 2007 and October 2025, including 19 fatal reports and 24 necrotising pancreatitis reports.
Key recommendations: stop treatment immediately if pancreatitis is suspected, do not restart if confirmed, use caution in patients with a history of pancreatitis, and report serious or fatal cases via Yellow Card.
MHRA requests that all suspected adverse drug reactions (ADRs) — including those already listed in the SmPC — are reported via the Yellow Card scheme. Reports from patients and carers are also welcome.
Reporting is especially valuable for: gastroparesis, serious GI events, thyroid abnormalities, pancreatitis, and any serious unexpected reactions.
Report online: yellowcard.mhra.gov.uk | Mobile app: Yellow Card app | In-practice: Medicines reconciliation systems
NICE published a consolidated adult summary for GLP-1 receptor agonists and tirzepatide covering type 2 diabetes, obesity and cardiovascular risk-reduction contexts. It brings together NG28, NG246 and technology appraisal logic so clinicians can compare recommendations when more than one indication could apply.
- For NG28 type 2 diabetes, semaglutide up to 1 mg weekly may be offered for adults with ASCVD in defined combination therapy contexts
- For early-onset T2DM, GLP-1 RA or tirzepatide can be considered in combination with metformin and an SGLT2 inhibitor where appropriate
- For adults with T2DM and obesity, GLP-1 RA or tirzepatide can be considered after at least 3 months of specified background treatment to help reach an individualised glycaemic target
- Stopping rules include becoming underweight and, depending on indication, failure to reach individualised glycaemic target
Clinicians should check the current NICE page, SmPC, BNF, MHRA Drug Safety Updates and local formulary before applying any row to a person with overlapping indications.
NICE lists tirzepatide for adults with type 2 diabetes under TA924 in the May 2026 adult summary. The summary notes ongoing work to align TA924 and NG28 recommendations, so clinicians should check both the appraisal and current local formulary before selecting tirzepatide for glycaemic treatment.
The SELECT cardiovascular risk-reduction indication creates overlap between obesity, cardiovascular disease and diabetes-prevention pathways. The NICE adult summary advises comparing relevant guidance rows where more than one use applies. Check the NICE guidance tracker and local commissioning route before prescribing specifically for CV risk reduction in non-diabetic obesity.
Clinical FAQs
Frequently asked questions
What recent safety alerts affect GLP-1 medicines?
Regulators including the MHRA, EMA and FDA have issued communications on perioperative aspiration risk, gastrointestinal effects and counterfeit or unlicensed products. Check the alerts page and official sources for the latest position.